UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2026
Commission
File Number: 001-42915
Alps
Group Inc
(Registrant’s
Name)
Unit
E-18-01 & E-18-02, Level 18, Icon Tower (East)
No.
1, Jalan 1/68F, Jalan Tun Razak
50400
Kuala Lumpur
Wilayah
Persekutuan, Malaysia
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information
Contained in this Form 6-K Report
Attached
hereto as Exhibit 99.1 is a press release dated February 23, 2026 issued by Alps Group Inc relating to a peer-reviewed case study
in the February 2026 edition of SAGE Open Medical Case Reports that highlights the effectiveness of Autologous Immune Enhancement Therapy.
Exhibits
| Exhibit
No. |
|
Description |
| 99.1* |
|
Press
Release dated February 23, 2026 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Alps
Group Inc |
| |
|
|
| Date:
February 23, 2026 |
By: |
/s/
Dr. Tham Seng Kong |
| |
Name:
|
Dr.
Tham Seng Kong |
| |
Title: |
Chief
Executive Officer and Director |
Exhibit
99.1
Alps
Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using
an In-House Developed Culture Protocol
KUALA
LUMPUR, Malaysia, February 23, 2026 - Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps
Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive,
preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case
Reports.
The
publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Company’s
in-house developed culture protocol. Natural Killer (NK) cells are a type of immune cell involved in the body’s natural defense
against abnormal cells.
The
patients were monitored pre- and post-infusion for hematological parameters, liver function, hypersensitivity reactions, inflammatory
markers as well as tumor markers to assess for potential NK cell-induced or any dose-dependent toxic/adverse reactions. The study provided
evidence of clinical tolerability of the autologous NK cells cultured using the Company’s proprietary protocol.
The
clinical case series study was registered with the National Medical Research Register, Ministry of Health Malaysia, with NMRR ID 25-00333-MUM.
Data collection and analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki and Malaysian Good
Clinical Practice guidelines. The study involved nine nonconsecutive patients who received NK cell infusions at ALPS Medical Centre between
2023 and 2024.
Dr.
Tham Seng Kong, Chief Executive Officer of Alps Group, stated, “Based on these preliminary observations, our in-house developed
NK cells appear to be safe for use. The NK cells also exhibited cytotoxicity toward in vitro cultured and co-incubated cancer cell models;
however, this was assessed using pilot cultures rather than as part of batch-release testing.”
A
notable aspect of this case series is the Company’s patent-pending, antibody-free culture method (Malaysian patent application
no. PI2025002484) which enables cost-effective, large-scale production of highly pure natural killer (NK) cells using basic culture media
and autologous plasma. This approach improves the safety profile of NK cells and lowers manufacturing barriers, potentially making advanced
immunotherapy more accessible and efficient.
Preliminary
case series data supports the safety of this method, positioning Alps Group at the forefront of scalable, next-generation autologous
immune cell therapy solutions. Together with preclinical GLP study data, the findings from this study are intended to support the design
of future clinical investigations in a broader patient population.
Details
of the study and its findings have been peer-reviewed and published in SAGE Open Medical Case Reports, accessible at:
https://journals.sagepub.com/doi/epub/10.1177/2050313X251376950
About
Alps Group
Alps
Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development,
medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally.
Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible
and affordable
Forward-Looking
Statements
Certain
statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of
“safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,”
“anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,”
“intend,” “plan,” “project” and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of
future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A
further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”)
by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement
made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which
it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may
be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor
Relations Contact
Andrew J. Barwicki
Tel: 516-662-9461
Email: andrew@barwicki.com
